1. Signaling Pathways
  2. Cell Cycle/DNA Damage
  3. CDK
  4. CDK2 Inhibitors

CDK2 Inhibitors

CDK1

CDK2

CDK3

CDK4

CDK5

CDK6

CDK7

CDK8

CDK9

CDK11

CDK12

CDK13

CDK14

CDK16

CDK19

CDC

CLK

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform CDK2 together.

Please try each isoform separately.

CDK2 Specific Inhibitors & Antagonists
Product Name CDK2 CDK1 CDK3 CDK4 CDK5 CDK6 CDK7 CDK8 CDK9 CDK12 CDK14 CDK16 CLK CDK2 Selectivity Purity
(E/Z)-Zotiraciclib
CDK2, IC50: 13 nM
                        Selective Inhibitor 99.96%
AUZ 454
CDK2(C118L/A144C), Kd: 9.7 nM
CDK2(A144C), Kd: 15.4 nM
CDK2(C118L), Kd: 18.6 nM
CDK2(WT), Kd: 50 nM
CDK2(C118L/A144C-Cyclin B), Kd: 134.1 nM
                        Selective Inhibitor 99.99%
CDK2-IN-4
cdk2/cyclin A, IC50: 44 nM
Cdk1/cyclin B, IC50: 86 μM
                      Selective Inhibitor ≥97.0%
Olomoucine
cdk2-cyclin A, IC50: 7 μM
cdk2-cyclin E, IC50: 7 μM
                        Selective Inhibitor ≥98.0%
BGG463
CDK2
                        Selective Inhibitor ≥98.0%
Desmethylglycitein
CDK2
CDK1
                      Selective Inhibitor ≥95.0%
CPS2
CDK2, IC50: 24 nM
                        Selective Inhibitor
CDK2-IN-7
CDK2/cyclinE, IC50: 50 nM
                        Selective Inhibitor
Abemaciclib
CDK2/cyclinE, IC50: 504 nM
CDK1/cyclinB1, IC50: 1627 nM
 
Cdk4/cyclin D1, IC50: 2 nM
CDK5/p35, IC50: 287 nM
Cdk5/p25, IC50: 355 nM
CDK6/cyclinD1, IC50: 10 nM
CDK7/Mat1/cyclinH1, IC50: 3910 nM
 
CDK9/cyclinT1, IC50: 57 nM
        Pan Inhibitor 99.83%
Dinaciclib
CDK2, IC50: 1 nM
CDK1, IC50: 3 nM
   
CDK5, IC50: 1 nM
     
CDK9, IC50: 4 nM
        Pan Inhibitor 99.36%
Samuraciclib hydrochloride hydrate
CDK2, IC50: 578 nM
CDK1, IC50: 1.8 μM
 
CDK4, IC50: 49 μM
CDK5, IC50: 9.4 μM
CDK6, IC50: 31 μM
CDK7, IC50: 41 nM
 
CDK9, IC50: 1.2 μM
        Pan Inhibitor 99.08%
Ro-3306
CDK2/cyclinE, Ki: 340 nM
CDK1, Ki: 20 nM
CDK1/cyclinB1, Ki: 35 nM
CDK1/cyclin A, Ki: 110 nM
                      Pan Inhibitor 98.54%
Abemaciclib methanesulfonate
CDK2/cyclinE, IC50: 504 nM
CDK1/cyclinB1, IC50: 1627 nM
 
Cdk4/cyclin D1, IC50: 2 nM
Cdk5/p25, IC50: 355 nM
CDK5/p35, IC50: 287 nM
CDK6/cyclinD1, IC50: 10 nM
CDK7/Mat1/cyclinH1, IC50: 3910 nM
 
CDK9/cyclinT1, IC50: 57 nM
        Pan Inhibitor ≥98.0%
Seliciclib
cdk2/cyclin A, IC50: 0.7 μM
Cdk2/cyclin E2, IC50: 0.7 μM
cdc2/cyclin B, IC50: 0.65 μM
   
CDK5/p35, IC50: 0.16 μM
                Pan Inhibitor ≥98.0%
Flavopiridol
CDK2/Cyc E, IC50: 170 nM
CDK1/Cyc B1, IC50: 30 nM
 
CDK4/Cyc D1, IC50: 100 nM
                  Pan Inhibitor 99.72%
Fadraciclib
CDK2
             
CDK9
        Pan Inhibitor 99.78%
SNS-032
CDK2, IC50: 38 nM
CDK1, IC50: 480 nM
 
CDK4, IC50: 925 nM
   
CDK7, IC50: 62 nM
 
CDK9, IC50: 4 nM
        Pan Inhibitor 99.49%
AZD-5438
cdk2-cyclin E, IC50: 6 nM
cdk2-cyclin A, IC50: 45 nM
cdk1-cyclin B1, IC50: 16 nM
 
cdk4-cyclin D1, IC50: 449 nM
cdk5-p25, IC50: 14 nM
cdk6-cyclin D3, IC50: 21 nM
cdk7-cyclin H, IC50: 821 nM
 
cdk9-cyclin T, IC50: 20 nM
        Pan Inhibitor 99.55%
AT7519
cdk2/cyclin A, IC50: 47 nM
Cdk1/cyclin B, IC50: 210 nM
 
Cdk4/cyclin D1, IC50: 100 nM
CDK5/p35, IC50: 13 nM
cdk6/cyclin D3, IC50: 170 nM
CDK7/Cyclin H/MAT1, IC50: 2400 nM
 
CDK9/Cyclin T, IC50: 10 nM
        Pan Inhibitor 99.76%
Kenpaullone
cdk2/cyclin A, IC50: 0.68 μM
CDK2/cyclinE, IC50: 7.5 μM
Cdk1/cyclin B, IC50: 0.4 μM
   
CDK5/p35, IC50: 0.85 μM
                Pan Inhibitor 98.01%
Samuraciclib hydrochloride
CDK2, IC50: 578 nM
CDK1, IC50: 1.8 μM
 
CDK4, IC50: 49 μM
CDK5, IC50: 9.4 μM
CDK6, IC50: 34 μM
CDK7, IC50: 41 nM
 
CDK9, IC50: 1.2 μM
        Pan Inhibitor 99.98%
YKL-5-124 TFA
CDK2, IC50: 1300 nM
         
CDK7, IC50: 53.5 nM
CDK7/Mat1/CycH, IC50: 9.7 nM
 
CDK9, IC50: 3020 nM
        Pan Inhibitor 98.59%
GSK 3 Inhibitor IX
cdk2/cyclin A, IC50: 300 nM
Cdk1/cyclin B, IC50: 320 nM
 
Cdk4/cyclin D1, IC50: 10 μM
CDK5/p35, IC50: 80 nM
                Pan Inhibitor ≥98.0%
Flavopiridol Hydrochloride
CDK2/Cyc E, IC50: 170 nM
CDK1/Cyc B1, IC50: 30 nM
 
CDK4/Cyc D1, IC50: 100 nM
                  Pan Inhibitor ≥98.0%
JNJ-7706621
CDK2/cyclinE, IC50: 3 nM
cdk2/cyclin A, IC50: 4 nM
Cdk1/cyclin B, IC50: 9 nM
CDK3/Cyclin E, IC50: 58 nM
Cdk4/cyclin D1, IC50: 253 nM
 
CDK6/cyclinD1, IC50: 175 nM
              Pan Inhibitor 99.96%
CGP60474
CDK2/cyclinE, IC50: 3 nM
cdk2/cyclin A, IC50: 4 nM
CDK1-Cyclin B, IC50: 26 nM
 
CDK4/cyclin D, IC50: 216 nM
Cdk5/p25, IC50: 10 nM
 
CDK7/cyclin H, IC50: 200 nM
 
CDK9/cycT, IC50: 13 nM
        Pan Inhibitor 98.70%
Milciclib
cyclin A/CDK2, IC50: 45 nM
cyclin E/CDK2, IC50: 363 nM
cyclin B/CDK1, IC50: 398 nM
 
cyclin D1/CDK4, IC50: 160 nM
   
cyclin H/CDK7, IC50: 150 nM
            Pan Inhibitor 99.89%
BMS-265246
CDK2/Cyc E, IC50: 9 nM
CDK1/cycB, IC50: 6 nM
 
CDK4/cycD, IC50: 230 nM
                  Pan Inhibitor 99.28%
Roniciclib
CDK2/cyclinE, IC50: 9 nM
Cdk1/cyclin B, IC50: 7 nM
 
CDK4/cyclin D, IC50: 11 nM
   
CDK7/Cyclin H/MAT1, IC50: 25 nM
 
CDK9/cyclinT1, IC50: 5 nM
        Pan Inhibitor 98.89%
(R)-CR8 trihydrochloride
cdk2/cyclin A, IC50: 0.072 μM
CDK2/cyclinE, IC50: 0.041 μM
CDK1/cyclinB1, IC50: 0.09 μM
   
Cdk5/p25, IC50: 0.11 μM
 
CDK7/cyclin H, IC50: 1.1 μM
 
CDK9/Cyclin T, IC50: 0.18 μM
        Pan Inhibitor 99.02%
CVT-313
cdk2/cyclin A, IC50: 0.5 μM
Cdk1/cyclin B, IC50: 4.2 μM
 
Cdk4/cyclin D1, IC50: 215 μM
                  Pan Inhibitor 99.76%
R547
CDK2/cyclinE, Ki: 3 nM
cdk2/cyclin A, IC50: 0.1 nM
CDK2/cyclinE, IC50: 0.4 nM
Cdk1/cyclin B, Ki: 2 nM
Cdk1/cyclin B, IC50: 0.2 nM
CDK3/Cyclin E, IC50: 0.8 nM
CDK4/cyclin D, Ki: 1 nM
CDK5/p35, IC50: 0.1 nM
cdk6/cyclin D3, IC50: 4 nM
CDK7/cyclin H, IC50: 171 nM
            Pan Inhibitor 99.66%
PHA-793887
cdk2/cyclin A, IC50: 8 nM
CDK2/cyclinE, IC50: 8 nM
Cdk1/cyclin B, IC50: 60 nM
 
Cdk4/cyclin D1, IC50: 62 nM
Cdk5/p25, IC50: 5 nM
 
CDK7/cyclin H, IC50: 10 nM
 
CDK9/cyclinT1, IC50: 138 nM
        Pan Inhibitor 99.25%
PHA-767491 hydrochloride
CDK2, IC50: 240 nM
CDK1, IC50: 250 nM
   
CDK5, IC50: 460 nM
     
CDK9, IC50: 34 nM
        Pan Inhibitor 99.91%
THZ2
CDK2, IC50: 222 nM
CDK1, IC50: 96.9 nM
   
CDK5, IC50: 134 nM
 
CDK7, IC50: 13.9 nM
CDK8, IC50: 6830 nM
CDK9, IC50: 194 nM
        Pan Inhibitor ≥95.0%
FN-1501
cdk2/cyclin A, IC50: 2.47 nM
   
Cdk4/cyclin D1, IC50: 0.85 nM
 
CDK6/cyclinD1, IC50: 1.96 nM
              Pan Inhibitor 99.71%
Atuveciclib
CDK2/CycE(h), IC50: 1000 nM
CDK1/CycB(h), IC50: 1100 nM
CDK3/CycE(h), IC50: 890 nM
 
CDK5/p35(h), IC50: 1600 nM
     
CDK9/CycT1, IC50: 13 nM
CDK9/CycT1(h), IC50: 6 nM
        Pan Inhibitor 99.20%
Riviciclib hydrochloride
cdk2-cyclin A, IC50: 0.224 μM
cdk2-cyclin E, IC50: 2.500 μM
CDK1-Cyclin B, IC50: 0.079 μM
 
cdk4-cyclin D1, IC50: 0.063 μM
 
cdk6-cyclin D3, IC50: 0.396 μM
   
CDK9- Cyclin T1, IC50: 0.020 μM
CDK9-cyclin H, IC50: 2.900 μM
        Pan 98.33%
Purvalanol A
cdk2-cyclin E, IC50: 35 nM
cdk2-cyclin A, IC50: 70 nM
cdc2-cyclin B, IC50: 4 nM
 
cdk4-cyclin D1, IC50: 850 nM
cdk5-p35, IC50: 75 nM
                Pan Inhibitor 99.11%
FMF-04-159-2
CDK2, IC50: 256 nM (in NanoBRET assay)
                 
CDK14/Cyclin Y, IC50: 39.6 nM (in NanoBRET assay)
    Pan Inhibitor 99.34%
CDK5 inhibitor 20-223
CDK2, IC50: 6.0 nM
     
CDK5, IC50: 8.8 nM
                Pan Inhibitor 99.64%
LDC000067
cdk2-cyclin A, IC50: 2441 nM
cdk1-cyclin B1, IC50: 5513 nM
 
cdk4-cyclin D1, IC50: 9242 nM
       
CDK9- Cyclin T1, IC50: 44 nM
        Pan Inhibitor 98.58%
BS-181 hydrochloride
CDK2/Cyc E, IC50: 0.88 μM
CDK1/cycB, IC50: 8.1 μM
 
CDK4/Cyc D1, IC50: 33 μM
CDK5/p35NCK, IC50: 3 μM
CDK6/cycD1, IC50: 47 μM
CDK7/CycH/MAT1, IC50: 0.021 μM
 
CDK9/cycT, IC50: 4.2 μM
        Pan Inhibitor ≥99.0%
Bisindolylmaleimide X hydrochloride
CDK2, IC50: 200 nM
                        Pan Antagonist 98.53%
CDK12-IN-E9
cdk2/cyclin A, IC50: 932 nM
         
CDK7/Cyclin H/MNAT1, IC50: 1210 nM
 
CDK9/cyclinT1, IC50: 23.9 nM
        Pan Inhibitor 99.20%
SY-5609
CDK2, Ki: 2600 nM
         
CDK7, Kd: 0.065 nM
 
CDK9, Ki: 960 nM
CDK12, Ki: 870 nM
      Pan Inhibitor 99.66%
Purvalanol B
cdk2/cyclin A, IC50: 6 nM
CDK2/cyclinE, IC50: 9 nM
cdc2/cyclin B, IC50: 6 nM
   
CDK5/p35, IC50: 6 nM
                Pan Inhibitor ≥97.0%
YKL-5-124
CDK2, IC50: 1300 nM
         
CDK7, IC50: 53.5 nM
CDK7/Mat1/CycH, IC50: 9.7 nM
 
CDK9, IC50: 3020 nM
        Pan Inhibitor 98.03%
CDKI-73
CDK2, IC50: 3.27 nM
CDK2, Ki: 3 nM
CDK1, IC50: 8.17 nM
CDK1, Ki: 4 nM
 
CDK4, IC50: 8.18 nM
 
CDK6, IC50: 37.68 nM
CDK7, IC50: 134.26 nM
CDK7, Ki: 91 nM
 
CDK9, IC50: 5.78 nM
CDK9, Ki: 4 nM
        Pan Inhibitor 99.58%
AT7519 Hydrochloride
cdk2/cyclin A, IC50: 47 nM
Cdk1/cyclin B, IC50: 210 nM
 
Cdk4/cyclin D1, IC50: 100 nM
CDK5/p35, IC50: 13 nM
cdk6/cyclin D3, IC50: 170 nM
CDK7/Cyclin H/MAT1, IC50: 2400 nM
 
CDK9/Cyclin T, IC50: 10 nM
        Pan Inhibitor 99.29%
K00546
cdk2/cyclin A, IC50: 0.5 nM
Cdk1/cyclin B, IC50: 0.6 nM
                   
CLK1, IC50: 8.9 nM
CLK3, IC50: 29.2 nM
Pan Inhibitor 98.78%
PROTAC CDK2/9 Degrader-1
CDK2, DC50: 62 nM
             
CDK9, DC50: 33 nM
        Pan Inhibitor 99.85%
SU9516
CDK2, IC50: 22 nM
CDK1, IC50: 40 nM
 
CDK4, IC50: 200 nM
                  Pan Inhibitor 99.83%
TL12-186
cdk2/cyclin A, IC50: 73 nM
             
CDK9/cyclinT1, IC50: 55 nM
        Pan Inhibitor ≥99.0%
NU6102
CDK2/cyclin A3, IC50: 5.4 nM
Cdk1/cyclin B, IC50: 9.5 nM
 
CDK4, IC50: 1.6 μM
                  Pan Inhibitor ≥95.0%
hSMG-1 inhibitor 11j
CDK2, IC50: 7.1 μM
CDK1, IC50: 32 μM
                      Pan Inhibitor 99.81%
AMG 925
CDK2, IC50: 375 nM
CDK1, IC50: 1.9 μM
 
CDK4, IC50: 3 nM
 
CDK6, IC50: 8 nM
              Pan Inhibitor 98.24%
(R)​-​CR8
cdk2/cyclin A, IC50: 0.072 μM
CDK2/cyclinE, IC50: 0.041 μM
Cdk1/cyclin B, IC50: 0.09 μM
   
Cdk5/p25, IC50: 0.11 μM
 
CDK7/cyclin H, IC50: 1.1 μM
 
CDK9/Cyclin T, IC50: 0.18 μM
        Pan Inhibitor ≥98.0%
Lerociclib dihydrochloride
cdk2/cyclin A, IC50: 1.5 μM
CDK2/cyclinE, IC50: 3.6 μM
CDK1/cyclinB1, IC50: 2.4 μM
 
Cdk4/cyclin D1, IC50: 1 nM
CDK5/p35, IC50: 832 nM
Cdk5/p25, IC50: 1.2 μM
cdk6/cyclin D3, IC50: 2 nM
CDK7/Cyclin H/MAT1, IC50: 2.4 μM
 
CDK9/Cyclin T, IC50: 28 nM
        Pan Inhibitor 99.74%
MC180295
cdk2-cyclin A, IC50: 233 nM
cdk2-cyclin E, IC50: 367 nM
CDK1-Cyclin B, IC50: 138 nM
CDK3-Cyclin E, IC50: 399 nM
CDK4-Cyclin D, IC50: 112 nM
cdk5-p35, IC50: 159 nM
cdk5-p25, IC50: 186 nM
cdk6-cyclin D3, IC50: 712 nM
CDK7-CycH/MAT1, IC50: 555 nM
 
CDK9- Cyclin T1, IC50: 5 nM
        Pan Inhibitor 98.41%
PNU112455A hydrochloride
CDK2, Km: 3.6 μM
     
CDK5, Km: 3.2 μM
                Pan Inhibitor 99.62%
NVP-LCQ195
cdk2/cyclin A, IC50: 2 nM
CDK2/cyclinE, IC50: 5 nM
Cdk1/cyclin B, IC50: 2 nM
CDK3/Cyclin E, IC50: 42 nM
 
Cdk5/p25, IC50: 1 nM
CDK5/p35, IC50: 1 nM
cdk6/cyclin D3, IC50: 187 nM
CDK7/Cyclin H/MAT1, IC50: 3564 nM
 
CDK9/cyclinT1, IC50: 15 nM
        Pan Inhibitor 99.80%
JSH-150
cdk2/cyclin A, IC50: 2.86 μM
Cdk1/cyclin B, IC50: 1.34 μM
   
Cdk5/p25, IC50: 4.64 μM
 
CDK7/Cyclin H/MNAT1, IC50: 1.72 μM
 
CDK9/cyclinT1, IC50: 1 nM
 
CDK14/Cyclin Y, IC50: 1.68 μM
CDK16/Cyclin Y, IC50: 292 nM
  Pan Inhibitor 98.36%
NU6140
cdk2-cyclin A, IC50: 0.41 μM
CDK1-Cyclin B, IC50: 6.6 μM
 
CDK4-Cyclin D, IC50: 5.5 μM
cdk5-p25, IC50: 15 μM
 
cdk7-cyclin H, IC50: 3.9 μM
            Pan Inhibitor ≥99.0%
BS-181
CDK2/Cyc E, IC50: 0.88 μM
CDK1/cycB, IC50: 8.1 μM
 
CDK4/Cyc D1, IC50: 33 μM
CDK5/p35NCK, IC50: 3 μM
CDK6/cycD1, IC50: 47 μM
CDK7/CycH/MAT1, IC50: 0.021 μM
 
CDK9/cycT, IC50: 4.2 μM
        Pan Inhibitor 98.10%
IV-361
CDK2, Ki: ≥1000 nM
         
CDK7, Ki: ≤50 nM
            Pan Inhibitor 98.64%
NU6027
CDK2, Ki: 1.3 μM
CDK1, Ki: 2.5 μM
                      Pan Inhibitor 99.35%
Alsterpaullone
cdk2/cyclin A, IC50: 15 nM
CDK2/Cyc E, IC50: 200 nM
Cdk1/cyclin B, IC50: 35 nM
   
CDK5/p35, IC50: 40 nM
                Pan Inhibitor ≥98.0%
NU2058
CDK2, IC50: 17 μM
CDK2, Ki: 12 μM
CDK1, IC50: 26 μM
                      Pan Inhibitor 99.01%
CAN508
CDK2/cyclinE, IC50: 20 μM
cdk2/cyclin A, IC50: 69 μM
Cdk1/cyclin B, IC50: 44 μM
 
Cdk4/cyclin D1, IC50: 13.5 μM
   
CDK7/cyclin H, IC50: 26 μM
 
CDK9/cyclinT1, IC50: 0.35 μM
        Pan Inhibitor 99.91%
AMG 925 HCl
CDK2, IC50: 375 nM
CDK1, IC50: 1.9 μM
 
CDK4, IC50: 3 nM
 
CDK6, IC50: 8 nM
              Pan Inhibitor 98.01%
AT7519 TFA
cdk2/cyclin A, IC50: 47 nM
Cdk1/cyclin B, IC50: 210 nM
 
Cdk4/cyclin D1, IC50: 100 nM
CDK5/p35, IC50: 13 nM
cdk6/cyclin D3, IC50: 170 nM
CDK7/Cyclin H/MAT1, IC50: 2400 nM
 
CDK9/Cyclin T, IC50: 10 nM
        Pan Inhibitor 98.16%
PHA-767491
CDK2, IC50: 240 nM
CDK1, IC50: 250 nM
   
CDK5, IC50: 460 nM
     
CDK9, IC50: 34 nM
        Pan Inhibitor
Samuraciclib
CDK2/cycE1, IC50: 578 nM
CDK1, IC50: 1.8 μM
 
CDK4, IC50: 49 μM
CDK5, IC50: 9.4 μM
CDK6, IC50: 34 μM
CDK7/CycH/MAT1, IC50: 41 nM
 
CDK9, IC50: 1.2 μM
        Pan Inhibitor
CDK9-IN-9
CDK2, IC50: 155 nM
             
CDK9, IC50: 1.8 nM
        Pan Inhibitor
IIIM-290
CDK2/A, IC50: 90 nM
             
CDK9/T1, IC50: 94 nM
        Pan Inhibitor
CDK12-IN-2
CDK2, IC50: >100 μM
         
CDK7, IC50: >10 μM
CDK7, IC50: >10 μM
 
CDK9, IC50: 16 μM
CDK12, IC50: 52 nM
      Pan Inhibitor
Riviciclib
cdk2-cyclin A, IC50: 0.224 μM
cdk2-cyclin E, IC50: 2.540 μM
CDK1-Cyclin B, IC50: 0.079 μM
 
cdk4-cyclin D1, IC50: 0.063 μM
 
cdk6-cyclin D3, IC50: 0.396 μM
   
CDK9- Cyclin T1, IC50: 0.020 μM
CDK9-cyclin H, IC50: 2.900 μM
        Pan Inhibitor
Lerociclib
cdk2/cyclin A, IC50: 1.5 μM
CDK2/cyclinE, IC50: 3.6 μM
CDK1/cyclinB1, IC50: 2.4 μM
 
Cdk4/cyclin D1, IC50: 1 nM
CDK5/p35, IC50: 0.832 μM
Cdk5/p25, IC50: 1.2 μM
cdk6/cyclin D3, IC50: 2 nM
CDK7/Cyclin H/MAT1, IC50: 2.4 μM
 
CDK9/Cyclin T, IC50: 28 nM
        Pan Inhibitor
BS-181 dihydrochloride
CDK2, IC50: 880 nM
     
CDK5, IC50: 3000 nM
 
CDK7, IC50: 21 nM
 
CDK9, IC50: 4200 nM
        Pan Inhibitor
Aloisine A
CDK2/cyclinA, IC50: 0.12 μM
CDK2/cyclinE, IC50: 0.4 μM
CDK1/cyclinB, IC50: 0.15 μM
   
CDK5/p35, IC50: 0.16 μM
                Pan Inhibitor
Bohemine
CDK2/cyclinE, IC50: 4.6 μM
cdk2/cyclin A, IC50: 83 μM
             
CDK9/cyclinT1, IC50: 2.7 μM
        Pan Inhibitor ≥98.0%
CDK12-IN-5
CDK2/cyclinE, IC50: 173 μM
             
CDK9/cyclinT1, IC50: 127 μM
CDK12, IC50: 23.9 nM
      Pan Inhibitor
CDK12-IN-6
CDK2/cyclinE, IC50: >20 μM
             
CDK9/cyclinT1, IC50: >20 μM
CDK12, IC50: 1.19 μM
      Pan Inhibitor
3-Methylthienyl-carbonyl-JNJ-7706621
CDK2/cyclinA, IC50: 2 nM
CDK1/cyclinB, IC50: 6.4 nM
 
CDK4, IC50: 0.11 μM
                  Pan Inhibitor
CDK12-IN-4
CDK2/cyclinE, IC50: >20 μM
             
CDK9/cyclinT1, IC50: >20 μM
CDK12, IC50: 0.641 μM
      Pan Inhibitor
Indirubin-5-sulfonate
cdk2/cyclin A, IC50: 35 nM
CDK2/cyclinE, IC50: 150 nM
Cdk1/cyclin B, IC50: 55 nM
 
Cdk4/cyclin D1, IC50: 300 nM
CDK5/p35, IC50: 65 nM
                Pan Inhibitor
hSMG-1 inhibitor 11e
CDK2, IC50: 7.1 μM
CDK1, IC50: 32 μM
                      Pan Inhibitor 99.18%
FN-1501-propionic acid
CDK2
             
CDK9
       
Ipivivint
CDK2, IC50: 0.002 μM
CDK1, IC50: 1.4 μM
CDK3, IC50: 0.022 μM
                    Inhibitor